每年研究成果
每年研究成果
個人檔案
研究專長
頭頸癌、鼻咽癌、泌尿系統癌症、臨床試驗、新藥開發
教育/學術資格
PhD, 臨床醫學研究所, 國立陽明交通大學
指紋
查看啟用 Peter Mu-Hsin Chang 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
- 1 類似的個人檔案
網路
國家/地區層面的近期外部共同作業。按一下圓點深入探索詳細資料，或
-
A generational comparison for unfavorable cancer of unknown primary in a single institute over 20 years
Tang, C. Y., Hang, J. F., Hung, Y. P., Chiu, N. C., Lai, J. I., Chen, M. H., Liu, C. Y., Yang, M. H., Chao, Y. & Chang, P. M. H., 2022, (Accepted/In press) 於: Cancer Medicine.研究成果: Article › 同行評審
開啟存取 -
BMX, a specific HDAC8 inhibitor, with TMZ for advanced CRC therapy: a novel synergic effect to elicit p53-, β-catenin- and MGMT-dependent apoptotic cell death
Ko, H. J., Chiou, S. J., Tsai, C. Y., Loh, J. K., Lin, X. Y., Tran, T. H., Hou, C. C., Cheng, T. S., Lai, J. M., Chang, P. M. H., Wang, F. S., Su, C. L., Huang, C. Y. F. & Hong, Y. R., 12月 2022, 於: Cell Communication and Signaling. 20, 1, 200.研究成果: Article › 同行評審
開啟存取 -
Dehydroepiandrosterone (DHEA) Sensitizes Irinotecan to Suppress Head and Neck Cancer Stem-Like Cells by Downregulation of WNT Signaling
Li, L. J., Li, C. H., Chang, P. M. H., Lai, T. C., Yong, C. Y., Feng, S. W., Hsiao, M., Chang, W. M. & Huang, C. Y. F., 13 7月 2022, 於: Frontiers in Oncology. 12, 775541.研究成果: Article › 同行評審
開啟存取 -
Efficacy of cetuximab-containing regimens in the treatment of recurrent/metastatic head and neck cancer after progression to immune checkpoint inhibitors
Lai, C. L., Chen, T. H., Chang, P. M. H., Tai, S. K., Chu, P. Y. & Yang, M. H., 1 6月 2022, 於: Journal of the Chinese Medical Association. 85, 6, p. 687-692 6 p.研究成果: Article › 同行評審
開啟存取 -
FAS receptor regulates NOTCH activity through ERK-JAG1 axis activation and controls oral cancer stemness ability and pulmonary metastasis
Li, L. J., Chang, P. M. H., Li, C. H., Chang, Y. C., Lai, T. C., Su, C. Y., Chen, C. L., Chang, W. M., Hsiao, M. & Feng, S. W., 12月 2022, 於: Cell Death Discovery. 8, 1, 101.研究成果: Article › 同行評審
開啟存取4 引文 斯高帕斯（Scopus）